<DOC>
	<DOCNO>NCT02434692</DOCNO>
	<brief_summary>The purpose study evaluate safety performance ARGOS-IO system patient POAG indicate cataract surgery .</brief_summary>
	<brief_title>Safety Performance Study ARGOS-IO ( Intraocular ) System Patients With Primary Open Angle Glaucoma ( POAG )</brief_title>
	<detailed_description>This clinical investigation prospective , open-label , multicenter , single-arm clinical investigation conduct two stage use Simon two-stage design . Subjects enrol follow : First stage : 11 patient Second stage : 11 patient An interim analysis perform 11 patient first stage complete 3 month follow-up visit . The trial stop 2 patient experience serious adverse device event ( SADE ) time . Otherwise enrollment resume trial continue additional 11 patient enrol stage 2 receive ARGOS-IO implant . A conclusion safety make total 2 total 22 patient experience SADE .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>1 . Mentally competent willing provide write informed consent 2 . Male female age ≥40 ≤85 year . Female subject childbearing potential must willing use adequate contraception must negative pregnancy test . 3 . Diagnosis primary openangle glaucoma ( POAG ) include high pressure glaucoma ( HPG ) , normal pressure glaucoma ( NPG ) ocular hypertension ( OH ) 4 . Sufficiently control intraocular pressure ( IOP ) 5 . Phakic eye 6 . Only one eye per patient may implant ARGOSIO implant 7 . Cataract surgery indicate . The medical indication cataract operation must give irrespective study participation . Potential study patient solicit participation clinical trial patient give consent cataract operation . 8 . Preoperative anterior chamber depth ( ACD ) ≥2.5 mm 9 . Axis length &gt; 22 mm 10 . Endothelial cell density cornea ≥2000 cells/mm² 11 . Subjects able willing attend schedule visit comply study procedure 1 . Any type glaucoma primary openangle glaucoma define inclusion criterion 3 2 . Severe POAG patient macular degeneration visual field loss 20 decibel ( dB ) bad 3 . Exudative agerelated macular degeneration , instable macular degeneration 30 day prior inclusion , macular edema 4 . Retinal detachment 5 . Corneal diseases 6 . Diabetes mellitus 7 . Connective tissue diseases 8 . History evidence severe inflammatory eye disease ( i.e . uveitis , retinitis , scleritis ) one eye within 6 month prior ARGOSIO implantation 9 . Intraocular surgical procedure ( ) within 6 month prior ARGOSIO implantation surgical procedure refractive eye surgery affect assessment IOP Goldmann applanation tonometry 10 . History eye tumor 11 . Ocular disease glaucoma may affect assessment visual acuity and/or IOP Goldmann applanation tonometry ( choroidal hemorrhage detachment , lens subluxation , thyroid ophthalmopathy ) 12 . Anterior chamber configuration put subject high risk develop angle closure glaucoma 13 . History extensive keloid formation 14 . Severe dry eye syndrome 15 . Subjects need undergo ancillary procedure study eye time implantation postoperative study period 16 . Any known intolerance hypersensitivity topical anesthetic , mydriatic , plaster silicone ( component device ) 17 . Existence active medical eye implant and/or active medical implant head/neck region 18 . Any contraindication intraocular lens ( IOL ) implantation choroidal hemorrhage , concomitant severe eye disease , excessive vitreous loss , extremely shallow anterior chamber , microphthalmos , nonagerelated cataract , posterior capsular rupture , severe corneal dystrophy , untraceable IOP , zonular separation , color vision deficiencies 19 . Severe generalized disease result life expectancy short year 20 . Any clinical evidence investigator feel would place subject increase risk placement device 21 . Currently pregnant breastfeed 22 . Participation study involve investigational drug device within past 30 day ongoing participation study investigational drug device 23 . Patients suitable study base surgeon 's evaluation 24 . Patients unable unwilling understand comply require study procedures 25 . Patients psychiatric disorder influence judgement autonomy 26 . Subject and/or immediate family member employee investigational site directly affiliate study , sponsor contract research organization . 27 . Enrollment fellow eye clinical study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Primary Open Angle Glaucoma</keyword>
	<keyword>POAG</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Cataract</keyword>
	<keyword>Surgery</keyword>
	<keyword>Ocular Pressure</keyword>
</DOC>